TP53 and breast cancer: In 2019, a study by Lan et al. (2019) indicated that treatment with rhamnetin increased caspase-3/9 activity, upregulated p53 protein and miR-34a expression, and downregulated Notch-1 expression, suggesting that rhamnetin induced apoptosis of human BC cells through the miR-34a/Notch-1 signaling pathway.